KIR2DS4 and glioblastoma: We recently reported that NK cells isolated from healthy donors with haplotype B, KIR2DS2, and centromeric A/B or B/B, telomeric A/A or A/B genotype were the most potent against GBM cells in vitro and in vivo in mice compared to donors with KIR2DS4 (haplotype A, centromeric A/A, telomeric A/A) and KIR2DS2-/KIR2DS4- negative donors (centromeric A/A, telomeric A/A, A/B, or B/B) (40).